Kevin Joseph Fitzgerald Sells 1,510 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,510 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the sale, the executive vice president directly owned 23,554 shares in the company, valued at $8,547,039.98. This represents a 6.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $370.33, for a total value of $848,055.70.
• On Monday, November 17th, Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $359.18 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The stock has a market cap of $47.45 billion, a PE ratio of 1,496.56 and a beta of 0.32. The company’s 50-day moving average price is $420.41 and its two-hundred day moving average price is $421.12.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Analysts maintain a generally constructive stance: ALNY carries a consensus “Moderate Buy” from sell‑side firms, supporting a bullish medium‑term view for the shares. Alnylam Pharmaceuticals, Inc. Receives Consensus Rating of “Moderate Buy” from Analysts
• Positive Sentiment: Needham published a bullish forecast, highlighting upside tied to Alnylam’s longer‑term (Alnylam 2030) growth plan — a catalyst that could support recovery if execution meets targets. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: Context/valuation pieces are circulating that reassess ALNY’s premium valuation versus the newly unveiled Alnylam 2030 plan — useful for investors weighing long‑range upside against current multiples. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: Analyst opinions are mixed across the healthcare coverage universe, with some firms trimming targets while others remain upbeat — this divergence contributes to higher intraday volatility. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) …
• Negative Sentiment: Concentrated insider selling: multiple senior executives — including CEO Yvonne Greenstreet and several EVPs — disclosed sizable share sales on Jan. 12–13 (individual sales in the $0.5M–$3.5M range), which typically increases near‑term sell pressure and raises investor caution. Alnylam Insiders Quietly Unload a Major Chunk of Stock in Synchronized Sell‑Off
• Negative Sentiment: Market reaction to the company’s ambitious 2026 guidance and the Alnylam 2030 plan was negative — coverage noted a sharp intraday slide after the announcement — and Bank of America issued a pessimistic forecast that may amplify selling pressure. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Bank of America lowered its outlook and flagged downside risk, adding to analyst‑driven selling pressure following the company’s strategic/guidance update. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Needham & Company LLC raised their target price on shares of Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the stock a “buy” rating in a report on Monday. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Jefferies Financial Group cut their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada increased their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, September 19th. Twenty-two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $490.96.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at $25,000. Salomon & Ludwin LLC acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth about $27,000. Caitong International Asset Management Co. Ltd purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Atlantic Union Bankshares Corp purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $30,000. Finally, Ameriflex Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $32,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.